Results 161 to 170 of about 1,921,670 (307)

Maternal and Neonatal Complications Associated with Breast Cancer Systemic Treatments—A VigiBase Disproportionality Analysis Study

Clinical Pharmacology &Therapeutics, EarlyView.
Pregnancy‐associated breast cancer (PrBC) presents therapeutic challenges. Understanding maternal–fetal safety of systemic anticancer therapies is critical. We performed a case/non‐case disproportionality analysis using the WHO global pharmacovigilance database up to January 2024, to evaluate maternal–fetal outcomes associated with breast cancer (BC ...
Rayan Kabirian, Floriane Jochum, Elise Dumas, Florence Coussy, Kevin Bihan, Bénédicte Lebrun‐Vignes, Barbara Pistilli, Marc‐Antoine Benderra, Lise Selleret, Laurent Chouchana, Fabien Reyal, Anne‐Sophie Hamy, Paul Gougis   +12 more
wiley   +1 more source

Ameliorative Effect of Lycopene and Capsaicinoid Glucoside in Acute Myeloid Leukemia. [PDF]

J Biochem Mol Toxicol
Shehzadi S, Shahid MA, Nazir S, Mansoor M, Ullah A, Shah FI, Ali ZTA.   +6 more
europepmc   +1 more source

Acute myeloid leukemia

HemaSphere, 2019
openaire   +3 more sources

Population Pharmacokinetics and Exposure‐Response Analyses to Support Cofetuzumab Pelidotin (ABBV‐647) Dose Optimization in Non‐Small Cell Lung Cancer Patients

Clinical Pharmacology &Therapeutics, EarlyView.
Cofetuzumab pelidotin (Cofe‐P) is an anti‐protein tyrosine kinase 7 (PTK7) antibody‐drug conjugate (ADC) being investigated for the treatment of adults with PTK7‐expressing, recurrent non‐small cell lung cancer (NSCLC). The first‐in‐human (FIH) trial demonstrated tolerability of dosages ≤ 2.8 mg/kg once every 3 weeks (Q3W) and ≤ 3.2 mg/kg Q2W ...
Carla Biesdorf, Melanie Rinas, Benjamin Engelhardt, Rabih Saab, Cen Guo, Cristiano Ferlini, Kevin J. Freise, Rajeev M. Menon, Akshanth R. Polepally   +8 more
wiley   +1 more source

Risk of Bias Associated with Varying Sampling Strategies for External Comparator Cohorts for Single‐Arm Trials: Insights from Aggressive Lymphoma

Clinical Pharmacology &Therapeutics, EarlyView.
Marketing authorizations for oncology drugs are often based on single‐arm trials (SATs), and real‐world data‐based external comparator cohorts (ECCs) are increasingly explored to contextualize results. In retrospective studies, comparators may be identified by time of diagnosis but included based on time of relapse; such sampling strategies can ...
Mikkel Runason Simonsen, Shiva Leisner, Ahmed Ludvigsen Al‐Mashhadi, Laurids Østergaard Poulsen, Matthew Maurer, Lasse Hjort Jakobsen, Tarec Christoffer El‐Galaly   +6 more
wiley   +1 more source

Citizen Science Gamers Enable Automated Flow Cytometry Gating Through Machine Learning

Cytometry Part A, EarlyView.
ABSTRACT Machine learning can greatly accelerate biomedical research but is fundamentally constrained by the scarcity of high‐quality labeled data. We introduce a scalable data‐generation framework based on citizen science and apply it to automated flow cytometry gating, a foundational but subjective step in immunology that limits reproducibility ...
Sebastiano Montante, Daniel Yokosawa, Leon Li, Alexander Butyaev, Mehrnoush Malek, Razzi Movassaghi, Quentin Michalchuk, Chieh‐Ting Jimmy Hsu, David Shmil, Albina Rahim, Andrea Cossarizza, Julia Boira Esteban, Kornél Erhart, Bergur Finnbogason, George Kelion, Hjalti Leifsson, Josh Rivers, David Ecker, Attila Szantner, Jérôme Waldispühl, Ryan R. Brinkman   +20 more
wiley   +1 more source

Flow cytometry‐based monitoring of chimeric antigen receptor (CAR) T cells: Reagent selection, assay design, and clinical utility

Cytometry Part B: Clinical Cytometry, EarlyView.
Abstract Accurate quantification of chimeric antigen receptor (CAR) T cells is essential for monitoring post‐infusion CART expansion and persistence and for real‐time clinical decision‐making. Multiparameter flow cytometry (MFC) enables rapid, live‐cell detection with absolute quantification and concurrent immunophenotypic characterization. This review
Jianhua Ling, Wei Wang, Sa A. Wang
wiley   +1 more source

Relapsing-Remitting Perimyocarditis and Emerging Acute Myeloid Leukemia. [PDF]

JACC Case Rep
Zipperer-Giblin MB, Bowman JI, Patel N, Rinde-Hoffman D.   +3 more
europepmc   +1 more source

Resistance mechanisms for BCL2-inhibition in acute myeloid leukemia

RESISTANCE MECHANISMS FOR BCL2-INHIBITION IN ACUTE MYELOID LEUKEMIA Resistance mechanisms for BCL2-inhibition in acute myeloid leukemia / Zuleeg, Maximilian (Rights reserved) (-
Zuleeg, Maximilian
core  

Coexistence of immunophenotypically normal and aberrant mast cells in patients with clonal mast cell diseases associates with more indolent subtypes and less severe disease characteristics

Cytometry Part B: Clinical Cytometry, EarlyView.
Abstract Aberrant antigen expression on mast cells (MCs) is one of the most accurate diagnostic markers for clonal MC diseases (CMCD). Although the coexistence of normal and pathologic MCs is frequently seen, the disease characteristics associated with it have been minimally investigated.
Abdulrazzaq Alheraky, Kees Meijer, Marije Nijk, Saskia K. Klein, Hanneke N. G. Oude Elberink, Ido P. Kema, André B. Mulder   +6 more
wiley   +1 more source